Who are BONT-A intra-prostatic injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Botox 100 UNT Injection, OnabotulinumtoxinA Injectable Product, BOTULINUM TOXIN TYPE B, Xeomin®, OnabotulinumtoxinA 145 UNT [Botox], Intradetrusor Botox Injections.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bont-a-intra-prostatic-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BONT-A intra-prostatic injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BONT-A intra-prostatic injection (BONT-A intra-prostatic injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Urology.

phase 3 Botulinum toxin SNARE complex (acetylcholine release machinery) Urology Small molecule Live · refreshed every 30 min

Target snapshot

BONT-A intra-prostatic injection (BONT-A intra-prostatic injection) — University Hospital, Bordeaux. Botulinum toxin type A injected directly into the prostate blocks acetylcholine release at nerve endings to reduce smooth muscle contractions and lower urinary symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BONT-A intra-prostatic injection TARGET	BONT-A intra-prostatic injection	University Hospital, Bordeaux	phase 3	Botulinum toxin	SNARE complex (acetylcholine release machinery)
Botox 100 UNT Injection	Botox 100 UNT Injection	Brigitte Schürch	marketed	Botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA Injectable Product	OnabotulinumtoxinA Injectable Product	University of Utah	marketed	Botulinum toxin	SNAP-25 (synaptosomal-associated protein 25)
BOTULINUM TOXIN TYPE B	BOTULINUM TOXIN TYPE B	Eisai Co., Ltd.	marketed	Neurotoxin; botulinum toxin	Synaptobrevin (VAMP)
Xeomin®	Xeomin®	ATGC Co., Ltd.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery at neuromuscular junction)
OnabotulinumtoxinA 145 UNT [Botox]	OnabotulinumtoxinA 145 UNT [Botox]	Beth Israel Deaconess Medical Center	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

Galderma R&D · 2 drugs in this class
Hexsel Dermatology Clinic · 2 drugs in this class
Seoul National University Hospital · 2 drugs in this class
University of Utah · 2 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
EuBiologics Co.,Ltd · 1 drug in this class
Allergan · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Beth Israel Deaconess Medical Center · 1 drug in this class
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BONT-A intra-prostatic injection — Competitive Intelligence Brief. https://druglandscape.com/ci/bont-a-intra-prostatic-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing